WHC is still in active development. Read this to understand our approach.
depiction of UYXAWHWODHRRMR-UHFFFAOYSA-N.svg
tripsit

hexobarbital

Check on tripsit

drugmap

Hexobarbital

Check on drugmap

wiki

Hexobarbital

Check on wiki

Data

InChI: InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)

Synonyms: Methylhexabital,Enhexymal, Cyclopan, 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl, Noctivane, 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID, Hexabarbital, 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure, Enhexymalum, Methexenyl, 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione, Esobarbitale, Sodium hexobarbital, Dorico, Enhexymal, Sombucaps, Hexobarbitone, 5-(delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure, N-Methyl-5-cyclohexenyl-5-methylbarbituric acid, Esobarbitale [Italian], Hexobarbital [INN:JAN], 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione, Evipan, Evipan (TN), 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid, 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione,Hexobarbitone, 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German], Hexanastab oral,5-(Cyclohex-1-enyl)-1,5-dimethylbarbituric acid, 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione, Methylhexabarbital, Hexobarbitalum [INN-Latin], Narcosan, Evipal,Hexobarbital, Cyclonal, (+-)-Hexobarbital, Hexenal (barbiturate), 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid,5-(1-Cyclohexenyl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione, Hexobarbital (JAN/INN), Citodon, Hexobarbital (VAN), 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione,Barbidorm, Somnalert, Citopan, 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid,Hexobarbitalum, Esobarbitale [DCIT], Citopan (TN), Hexobarbitonum, Sombulex

Estimated data

Solubility: -1.886 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 38.5% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.